2 of the Best Dividend Stocks to Buy With $5,000 in November

Source The Motley Fool

Key Points

  • Johnson & Johnson raised its guidance again, and Icotyde is off to a strong start.

  • Walmart’s higher-margin businesses could lift profits over the long run.

  • They have increased their payouts for more than 100 consecutive years combined.

  • Motley Fool Issues Rare "Total Conviction" Buy Alert ›

Investors with different goals and preferences will gravitate toward different companies, even if they have the same investment strategy. That's why it's so hard to come up with "the best" of any category of stocks. But we can still give it a try. Consider the following two companies: Johnson & Johnson (NYSE:JNJ) and Walmart (NASDAQ:WMT). Both are longtime market leaders with excellent dividend programs and are arguably among the top income stocks, given their impressive track records.

For those with $5,000 to spare (make sure it isn't set aside for emergencies), Johnson & Johnson and Walmart are two of the first dividend stocks I'd recommend buying this month. Here is why.

Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our analysts, we’re only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »

Seedlings grow from rising stacks of coins beside a watering can and piggy bank, symbolizing savings growth.

Image source: Getty Images.

1. Johnson & Johnson

Johnson & Johnson has shown its resilience this year. Despite macroeconomic problems, a major U.S. patent cliff it experienced last year, and several of its medicines being targeted by government-led drug price negotiations, the healthcare giant has performed well. Third-quarter revenue increased by 5.9% year over year to $25.4 billion.

Johnson & Johnson's adjusted earnings per share declined 7.5% year over year to $2.59, primarily due to acquisition-related expenses. Overall, the business is healthy, and Johnson & Johnson once again increased its guidance for the full fiscal year 2026. The company now expects operational sales of $100.7 billion at the midpoint, representing a 6.9% year-over-year increase, versus midpoint sales and year-over-year growth of $100.6 billion and 6.8% year-over-year for its previous guidance.

Johnson & Johnson has also made meaningful clinical and regulatory progress this year, which should help the company boost sales and navigate patent cliffs over the medium term. In March, the company earned approval for Icotyde, a medicine for plaque psoriasis. It has had an impressive commercial ramp-up so far. As management noted, more than 20,000 patients have initiated treatment with Icotyde so far.

The company believes this drug can generate more than $5 billion in peak annual sales. And it boasts several other brand-new approvals or pipeline candidates that it believes can approach or even exceed the $5 billion annual sales milestone. We haven't even mentioned Johnson & Johnson's medtech business, where it has also made progress this year.

The company has earned clearance for the Ottava system, a robotic-assisted surgery device that will help it tap into an underpenetrated market. Johnson & Johnson looks unstoppable right now, and the company could continue delivering excellent returns for a while, especially once we factor in the dividend, which investors should seriously consider reinvesting.

Johnson & Johnson is a Dividend King, a company with a minimum of 50 consecutive annual dividend increases. Investors can get 17 shares of Johnson & Johnson with $5,000 right now. That'd be money well spent.

2. Walmart

Walmart has also performed well this year, despite economic headwinds that have weighed on much of the retail industry. In the second quarter of its fiscal year 2027, which ended July 31, the company's revenue increased by 5.9% year over year to $187.9 billion. Adjusted EPS rose 19.1% year over year to $0.81. Importantly, membership revenue, e-commerce sales, and advertising revenue all grew much faster than retail sales.

These are three crucial, higher-margin businesses that should help lift the company's profits over the long run. Here's another important point to consider. While many legacy retailers went out of business -- or are currently struggling to stay in business -- because they failed to capitalize on the shift toward e-commerce, Walmart made no such mistake.

It currently stands as the second largest e-commerce player in the U.S. That highlights the company's ability to capitalize on new technologies, and it is doing the same with artificial intelligence (AI). Walmart is leveraging AI across much of its business, including in optimizing inventory management and improving supply chain efficiency. It is also using AI to personalize customers' shopping experiences, which can lead to higher sales volume.

Walmart's AI efforts could make a meaningful impact over the long run. Meanwhile, the company still has many of the same strengths that made it so successful. It is one of the largest retailers in the U.S., with a vast network of locations -- 90% of the U.S. population lives within 10 miles of one of the company's stores. Further, Walmart leverages its large retail footprint to negotiate attractive prices and discounts with wholesalers and passes those cost savings onto customers. The result: Walmart tends to offer lower prices for items.

These are important competitive advantages that could enable the company to perform well over the long run, while continuously raising its dividends. Walmart is also a Dividend King -- it has raised its payouts for 53 consecutive years. Investors can buy 38 shares of the company for $5,000 right now. For long-term dividend-seeking investors, that might be a great move.

Should you buy stock in Johnson & Johnson right now?

Before you buy stock in Johnson & Johnson, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Johnson & Johnson wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $327,620!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $959,410!*

Now, it’s worth noting Stock Advisor’s total average return is 802% — a market-crushing outperformance compared to 205% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 17, 2026.

Prosper Junior Bakiny has positions in Johnson & Johnson and Walmart. The Motley Fool has positions in and recommends Walmart. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Nvidia reports tomorrow with an interim CEO — $108 billion is the easy numberNvidia closed at 162.85 on Friday, down 12.75% on the week and 32% below its 6 October record, with market value down to $3.92 trillion. The Q3 bar is $108 billion ±2%, and consensus already sits at $108.7 ~ 108.8 billion, so the revenue line is not where the surprise lives. The number that decides the reaction is the 71 ~ 72% Q4 gross-margin trough, followed by a Q4 guide against a $124.9 billion consensus. This piece prices the print, marks the 158.39 line and lays out the three scenarios in a table.
Author  Irene Q.
Nov 16, Mon
Nvidia closed at 162.85 on Friday, down 12.75% on the week and 32% below its 6 October record, with market value down to $3.92 trillion. The Q3 bar is $108 billion ±2%, and consensus already sits at $108.7 ~ 108.8 billion, so the revenue line is not where the surprise lives. The number that decides the reaction is the 71 ~ 72% Q4 gross-margin trough, followed by a Q4 guide against a $124.9 billion consensus. This piece prices the print, marks the 158.39 line and lays out the three scenarios in a table.
placeholder
Anthropic is six times oversubscribed at $1.4 trillion while Nvidia is down 32% — the AI trade has two pricesAnthropic lists on Nasdaq as ANT on Thursday at $70 ~ $78 a share, raising up to $64.4 billion at a target valuation near $1.4 trillion, and the book is reportedly six times covered. In the same six weeks, Nvidia has fallen 32% and the QQQ is 10.9% below its October peak. Private capital and public markets are marking the same AI complex at two very different prices. This piece separates the two books: what the S-1 shows, who is anchoring the $26 billion private placement, and what Thursday's debut would have to do to change the public tape.
Author  Irene Q.
Nov 16, Mon
Anthropic lists on Nasdaq as ANT on Thursday at $70 ~ $78 a share, raising up to $64.4 billion at a target valuation near $1.4 trillion, and the book is reportedly six times covered. In the same six weeks, Nvidia has fallen 32% and the QQQ is 10.9% below its October peak. Private capital and public markets are marking the same AI complex at two very different prices. This piece separates the two books: what the S-1 shows, who is anchoring the $26 billion private placement, and what Thursday's debut would have to do to change the public tape.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 16, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 16, 2026. Read on for the details.
Author  Mitrade
Nov 16, Mon
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 16, 2026. Read on for the details.
placeholder
Weekly Report: DXY 103.41, 10-year 5.15%, AUD carry 3bp — three FX regimes flipped in one weekThe dollar index rose 1.09% to 103.41, a 19-month high, while the US 10-year closed at 5.154% and the Australia-US two-year spread collapsed to about 3 basis points from 36. EURUSD fell 1.59% to 1.1024, USDJPY rose 1.51% to 159.78 and AUDUSD fell 1.79% to 0.6764, a 10-month low. Three FX regimes — the broad dollar, the US rate level and the Australian carry premium — flipped in the same week. This report marks the thresholds, ranks which one can flip back first, and lists the week's calendar.
Author  Irene Q.
Nov 16, Mon
The dollar index rose 1.09% to 103.41, a 19-month high, while the US 10-year closed at 5.154% and the Australia-US two-year spread collapsed to about 3 basis points from 36. EURUSD fell 1.59% to 1.1024, USDJPY rose 1.51% to 159.78 and AUDUSD fell 1.79% to 0.6764, a 10-month low. Three FX regimes — the broad dollar, the US rate level and the Australian carry premium — flipped in the same week. This report marks the thresholds, ranks which one can flip back first, and lists the week's calendar.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 17, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 17, 2026. Read on for the details.
Author  Mitrade
18 hours ago
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 17, 2026. Read on for the details.
goTop
quote